Frontlight ResearchEarly access
Taking peoplePhase 2
A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
Key facts
- Who runs it
- MiNK Therapeutics
- Where
- Houston, San Antonio, and San Francisco, United StatesSee the 3 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 90 people, planned
- Started
- 26 May 2026
- Expected to end
- Aug 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- agenT-797
- Placebo
- Standard of Care (SOC)
- Record updated
- 26 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Admission to an intensive care unit (ICU) with severe pneumonia of any etiology (viral, bacterial, fungal, or mixed), with and without trauma based on clinical suspicion
- Acute hypoxemic respiratory failure (AHRF)
- Evidence of moderate to severe acute respiratory distress syndrome (ARDS) based on Global ARDS criteria
- Onset of severe pneumonia with AHRF ≤7 days prior to informed consent
Who cannot take part
- Current participation in another interventional clinical trial, or receipt of an investigational medicinal product within 30 days prior to screening, unless reviewed and approved in writing by the medical monitor; Note: Other protocol-defined inclusion/exclusion criteria may apply
- History of cytokine release syndrome, as documented in the medical record or reported by the participant, legally authorized representative, or close relative
- More than two vasopressors to maintain a mean arterial pressure ≥65 millimeters of mercury at the time of informed consent
- Pregnancy or breastfeeding
Where in United States
Also in 1 other country, 1 site
- Children's Memorial Hermann HospitalHouston, United StatesContact: Charles Cox, MD (principal investigator)Not yet recruiting
- University HospitalSan Antonio, United StatesContact: Donald Jenkins, MD (principal investigator)Not yet recruiting
- UCSF Medical Center at Parnassus HeightsSan Francisco, United StatesContact: Michael Matthay, MD (principal investigator)Not yet recruiting
About the trial
What the trial wants to find out
This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).
The 2 groups in the trial
- agenT-797 plus SOCTreatment being tested
Participants will receive agenT-797 and SOC.
Treatment: agenT-797 and Standard of Care (SOC)
- Placebo plus SOCPlacebo, for comparison
Participants will receive placebo and SOC.
Treatment: Placebo and Standard of Care (SOC)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 2 Adaptive Randomized, Placebo -Controlled Trial of agenT-797 + Standard of Care Vs. Placebo + Standard of Care in Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure (AHRF) By Global ARDS Criteria
- Record updated
- 26 June 2026